The Significance of the Subcutaneous Opdivo FDA Approval in Solid Tumors
The Dec. 27, 2024, Food and Drug Administration (FDA) approval of the subcutaneous injection formulation of Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for patients with solid tumors opened up new treatment avenues for patients who are eligible for …